John M. Amatruda

A graduate of Yale University, Dr. Amatruda received his MD degree from the Medical College of Wisconsin and did his internship and residency in Internal Medicine and Fellowship in Endocrinology and Metabolism at The Johns Hopkins Hospital. He is board certified in internal medicine and in Endocrinology and Metabolism. Dr. Amatruda was a Professor of Medicine at The University of Rochester School of Medicine where he was Director of the Clinical Research Center. He left the University of Rochester to start and run a drug discovery group at Bayer Corporation where he was Vice President and Therapeutic Area Research Head as well as an Adjunct Professor of Medicine at Yale University School of Medicine. He assisted in the approval of Acarbose and his group put several compounds into clinical development.

Dr. Amatruda left Bayer to become the Vice President and Therapeutic Area Head for Metabolism and Atherosclerosis at Merck & Co., Inc.. This group was responsible for the approval of 3 drugs, Vytorin, Januvia, and Janumet. He was also interim Therapeutic Area Head for Cardiovascular. Most recently Dr. Amatruda was Senior Vice President and Franchise Head for Diabetes and Obesity and a member of the Research Management Committee. He retired from Merck in Nov 2009 and is currently a consultant, is on several Boards of Directors, is a founder in biotech companies and an Adjunct Professor of Medicine at Yale University. He continues to see patients in a teaching capacity. Dr Amatruda is an author on over 160 publications.